Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
To compare the efficacy and safety of tislelizumab combined with FOLFOX or combined with POF in the treatment of locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma with CPS≥1
Gastric Cancer
DRUG: Tislelizumab|DRUG: Oxaliplatin injection|DRUG: Levo-Leucovorin|DRUG: 5-fluorouracil|DRUG: Paclitaxel
progression free survival, The length of time from enrollment until the time of progression of disease (PFS, progression-free survival), 4 years
Objective response rate, Clinical response of treatment according to RESIST v1.1 criteria (ORR, objective response rate), every 4 weeks|Overall survival, The length of time from enrollment until the time of death (OS, overall survival)., 4 years
To compare the efficacy and safety of tislelizumab combined with FOLFOX or combined with POF in the treatment of locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma with CPS≥1